Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Lack Of VC Industry In Asia Means Public Institutions Need To Step In and Take On Risk

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Public institutions will need to step in and narrow the sizable gap between early research and commercialization in much of Asia, experts told an April 16 panel at the BioMedical Asia conference in Singapore

You may also be interested in...



Dx Assays Opens R&D Lab As Singapore’s First Developer Of Molecular Diagnostic Assays

PERTH, Australia - Dx Assays, Singapore's first commercial developer of molecular diagnostic assays, opened its new R&D center in Singapore Sept. 8

Dx Assays Opens R&D Lab As Singapore’s First Developer Of Molecular Diagnostic Assays

PERTH, Australia - Dx Assays, Singapore's first commercial developer of molecular diagnostic assays, opened its new R&D center in Singapore Sept. 8

Singapore Continues To Attract MNCs; Hill-Rom The Latest To Open Innovation Center In Country

SHANGHAI - Worldwide medical technology and device maker Hill-Rom opened its Asia-Pacific Innovation Center in Singapore Aug. 24. The new center will focus on research and development in micro-electronics and embedded software

Table

View full table

Tags:
Latest Headlines

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

Normality Reasserts Itself For Biotech IPOs

See All
UsernamePublicRestriction

Register

SC068434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By